List of Excipients in Branded Drug ZERBAXA

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Merck Sharp & Dohme LLC	ZERBAXA	ceftolozane and tazobactam	67919-030	ANHYDROUS CITRIC ACID	2036-02-14
Merck Sharp & Dohme LLC	ZERBAXA	ceftolozane and tazobactam	67919-030	ARGININE	2036-02-14
Merck Sharp & Dohme LLC	ZERBAXA	ceftolozane and tazobactam	67919-030	SODIUM CHLORIDE	2036-02-14

Zerbaxa Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Zerbaxa is a low-excipient, injectable antibiotic whose commercial differentiation depends less on novel inactive ingredients than on vial presentation, reconstitution performance, stability, infusion convenience, and hospital procurement economics. The product contains ceftolozane sulfate and tazobactam sodium in a sterile powder for intravenous infusion. The U.S. label identifies no inactive ingredients in the drug product; preparation requires dilution with an approved intravenous solution before administration.[1]

The strongest excipient-related opportunities are ready-to-use or ready-to-administer presentations, improved in-use stability, reduced preparation steps, and compatibility with automated hospital compounding systems. Any commercial strategy must preserve the product's concentration, pH, particulate profile, sterility assurance, and beta-lactam stability while addressing renal-dose variation and hospital workflow.

What is the Zerbaxa formulation and which excipients does it contain?

Zerbaxa is supplied as a single-dose vial containing:

Component	Amount per vial	Function
Ceftolozane sulfate	Equivalent to 1 g ceftolozane	Antibacterial active
Tazobactam sodium	Equivalent to 0.5 g tazobactam	Beta-lactamase inhibitor
Inactive ingredients	None listed in the U.S. prescribing information	No formulation excipient disclosed

The product is administered by intravenous infusion after reconstitution and further dilution. The labeled dose for adults with normal renal function is generally 1.5 g every eight hours for complicated urinary tract infection or complicated intra-abdominal infection, with metronidazole used for the latter indication. The hospital-acquired and ventilator-associated bacterial pneumonia dose is 3 g every eight hours.[1]

The different dose regimens create a commercial requirement for accurate preparation at multiple strengths. Renal impairment requires dosage adjustment, increasing the value of presentations that minimize calculation and compounding errors.

Why does Zerbaxa use a no-excipient powder formulation?

The powder presentation supports long-term storage of a beta-lactam antibiotic combination while avoiding unnecessary formulation components. Ceftolozane and tazobactam are supplied as separate active pharmaceutical ingredients in a sterile, lyophilized or otherwise dried vial presentation rather than as a ready-to-infuse liquid.

A no-excipient formulation has several advantages:

• Lower risk of excipient-related hypersensitivity or intolerance.
• Fewer compatibility concerns with infusion solutions.
• Simplified composition and analytical release testing.
• Reduced regulatory burden for novel inactive ingredients.
• Lower risk that an excipient will affect the stability of either active ingredient.
• Easier global registration where excipient restrictions differ by jurisdiction.

The tradeoff is greater preparation burden. Hospitals must reconstitute the vial, withdraw the required volume, dilute the solution, label the final container, and administer the infusion within the labeled stability window. That workflow creates the principal excipient and presentation opportunity.

What diluents and preparation conditions are used for Zerbaxa?

The U.S. prescribing information permits reconstitution with Sterile Water for Injection or 0.9% Sodium Chloride Injection. The reconstituted solution is then diluted in an infusion bag containing 0.9% Sodium Chloride Injection or 5% Dextrose Injection.[1]

The labeled preparation sequence is commercially important:

1. Reconstitute the vial.
2. Allow the powder to dissolve.
3. Withdraw the required volume.
4. Transfer the solution to a compatible infusion bag.
5. Administer by intravenous infusion.

The product should not be mixed with other drugs in the same solution unless compatibility has been established. The label also requires visual inspection for particulate matter and discoloration before administration.[1]

For hospital customers, the practical formulation questions are:

• How quickly does the vial dissolve?
• Does reconstitution produce foaming or require extended agitation?
• Is the solution stable at refrigerated and room temperatures?
• Does the product remain compatible with common infusion bags and tubing?
• Can the solution be prepared in an automated compounding device?
• Does the formulation tolerate transport after compounding?
• Can pharmacies prepare doses in advance without compromising potency?

These attributes can be protected through formulation, container-closure, manufacturing, and use patents even when the originator drug contains no inactive ingredients.

What excipient strategies could improve Zerbaxa commercial value?

Ready-to-administer liquid bags

A ready-to-administer presentation could eliminate vial reconstitution and reduce pharmacy labor. The main technical barrier is chemical stability in an aqueous environment. Beta-lactam antibiotics may undergo hydrolysis or other degradation in solution, particularly at elevated temperatures or over extended storage periods.

A commercially viable bag would require:

• Demonstrated potency retention through the labeled shelf life.
• Control of degradation products for both ceftolozane and tazobactam.
• Container compatibility with polyolefin or other infusion materials.
• Low extractables and leachables.
• Sterility maintenance through storage and administration.
• Defined hold times after removal from refrigeration.
• Stability across the labeled dose concentrations.

A ready-to-use product would compete on total cost of care rather than active-ingredient price. The economic proposition is strongest in intensive-care units, emergency departments, outpatient parenteral antimicrobial therapy, and hospitals with centralized pharmacy compounding.

Extended-stability premixes

A premixed vial or bag with a longer post-preparation stability window could reduce wastage. This is especially relevant for Zerbaxa because dosing varies by infection type and renal function. Hospitals may discard partially prepared doses when patient renal function changes or treatment is discontinued.

A formulation program could target:

• 24- to 48-hour refrigerated stability.
• A defined room-temperature administration window.
• Compatibility with standard elastomeric infusion pumps.
• Reduced overfill and lower residual volume.
• Barcode-enabled dose identification.

The commercial benefit would come from lower discarded product and fewer pharmacy interventions.

Alternative infusion containers

A container system using a dual-chamber bag could separate the dry antibiotic from the diluent until administration. Activation immediately before use would avoid long-term aqueous instability while providing a ready-to-administer workflow.

Dual-chamber systems can preserve a dry beta-lactam powder and standardize reconstitution. They also create potential intellectual-property positions around:

• Chamber geometry.
• Frangible seals.
• Mixing sequence.
• Oxygen control.
• Moisture barriers.
• Closure and port configuration.
• Automated activation.

The principal risks are device cost, manufacturing complexity, and the need to validate complete mixing across the intended dose range.

Pharmacy-compounding formats

A high-concentration vial or multi-dose institutional container could reduce the number of manipulations. That strategy would require careful evaluation of sterility, preservative use, container puncture limits, and in-use stability. A preservative-containing multidose format would introduce new safety and regulatory issues and would not necessarily be appropriate for critically ill patients.

A more realistic opportunity is a single-dose vial optimized for rapid dissolution and automated compounding. The value proposition would be operational rather than pharmacological.

What formulation patents could protect Zerbaxa improvements?

Formulation-related patent protection could cover several technical categories:

Patent category	Potential subject matter	Commercial purpose
Aqueous stability	pH control, concentration range, buffer system, degradation suppression	Ready-to-use liquid or premix
Dry powder stability	Residual moisture, cake structure, drying cycle, bulk density	Longer shelf life and faster reconstitution
Container closure	Moisture barrier, vial stopper, dual-chamber system	Preserves potency and sterility
Infusion compatibility	Specific bags, tubing, filters, and pump systems	Reduces administration failures
Reconstitution	Mixing method, dilution sequence, concentration limits	Standardizes pharmacy preparation
Manufacturing	Sterile filtration, aseptic filling, lyophilization, impurity control	Protects cost and quality advantages
Administration	Premixed dose systems and renal-dose kits	Reduces preparation error

The strongest formulation claims would generally require measurable technical results, such as improved stability, lower degradation, faster reconstitution, reduced particulates, or improved container compatibility. Broad claims limited to the use of a conventional diluent would face greater validity and design-around pressure.

When does Zerbaxa lose exclusivity and what is its FDA status?

Zerbaxa was approved by the FDA in December 2014 for complicated intra-abdominal infections and complicated urinary tract infections. The FDA later approved the hospital-acquired and ventilator-associated bacterial pneumonia indication in 2019.[2]

The product received Qualified Infectious Disease Product treatment under the Generating Antibiotic Incentives Now framework. QIDP designation can provide a five-year extension to applicable exclusivity periods. Zerbaxa's new chemical entity exclusivity and QIDP-related benefits were significant to the initial U.S. market protection period, but regulatory exclusivity is distinct from patent protection.[2][3]

The FDA Orange Book identifies approved drug products and listed patents for the relevant reference product. Patent status can change through expiration, terminal disclaimers, litigation, settlement, or later listing activity. Any generic launch analysis must review the current Orange Book entry, FDA approval history, and litigation docket together rather than relying on the original approval date.[3]

What generic entry risks exist for Zerbaxa?

Zerbaxa is a small-molecule antibacterial combination, so the principal U.S. competition risk is an abbreviated new drug application rather than a biosimilar application. A generic applicant would need to address:

• Pharmaceutical equivalence of ceftolozane and tazobactam.
• Equivalent strength and dosage form.
• Sterility and particulate requirements.
• Reconstitution and dilution instructions.
• Bioequivalence or applicable waiver requirements.
• Listed patents and regulatory exclusivities.
• Manufacturing controls for the two-component drug product.

The lack of inactive ingredients in the labeled drug product may simplify pharmaceutical-equivalence analysis. It does not remove challenges involving sterile manufacture, impurity control, powder uniformity, moisture exposure, and compatibility after reconstitution.

A Paragraph IV challenge could target listed patents covering the drug combination, crystalline or salt forms, manufacturing methods, use in defined infections, or formulation and presentation. A generic could also seek a section viii carve-out for a patented method of use, subject to the scope of the listed claims and FDA labeling requirements.

Which companies could challenge Zerbaxa?

Potential challengers would most likely include generic injectable manufacturers with sterile beta-lactam capacity. Relevant capabilities include:

• Aseptic vial filling.
• Lyophilization or sterile powder processing.
• High-potency antibiotic containment.
• Injectable stability programs.
• Hospital procurement relationships.
• FDA experience with complex parenteral products.

The commercial threshold is higher than for a conventional oral generic. Ceftolozane/tazobactam requires two active ingredients, sterile powder processing, and a product-specific preparation procedure. The market may support limited competition rather than a large number of entrants because manufacturing complexity and hospital formulary adoption can constrain returns.

How strong is the Zerbaxa excipient and formulation estate?

The commercial strength of the excipient estate is likely lower than the value of the active-ingredient, combination, use, and manufacturing estate because the U.S. label identifies no inactive ingredients. The most defensible future formulation positions would be linked to measurable performance improvements.

Stronger claim areas

• Stable aqueous presentations.
• Dual-chamber systems.
• Defined concentration and pH ranges tied to improved stability.
• Container systems that reduce moisture or oxygen exposure.
• Manufacturing processes that reduce degradation impurities.
• Premixed products with validated storage and administration windows.

Weaker claim areas

• Use of conventional saline or dextrose without a demonstrated technical effect.
• Generic claims to routine vial reconstitution.
• Broad claims covering standard infusion bags.
• Formulations that do not distinguish over the labeled powder product.
• Claims lacking comparative stability or compatibility data.

What licensing opportunities exist for Zerbaxa formulation technology?

Licensing opportunities are more likely to involve enabling technology than the active pharmaceutical ingredient itself. Potential partners include:

• Injectable formulation companies with beta-lactam stabilization platforms.
• Dual-chamber bag manufacturers.
• Contract development and manufacturing organizations.
• Automated pharmacy-compounding companies.
• Hospital software and barcode-dose management vendors.
• Specialty distributors serving outpatient infusion providers.

A licensing package could combine formulation know-how, container technology, stability data, and manufacturing transfer rights. Royalty economics would depend on whether the technology creates a differentiated FDA-approved presentation or only reduces manufacturing cost.

The most attractive deal structure would likely link payments to approval, commercial launch, and sales of a ready-to-administer presentation. A formulation platform that applies to other unstable injectable antibiotics could command greater value than a Zerbaxa-only license.

How does Zerbaxa compare with competing injectable antibiotics?

Product	Active drug type	Formulation opportunity	Main competitive issue
Zerbaxa	Ceftolozane/tazobactam	Ready-to-use or dual-chamber presentation	Preparation burden and price
Avycaz	Ceftazidime/avibactam	Stability, premix, renal-dose workflow	Similar hospital IV workflow
Vabomere	Meropenem/vaborbactam	Reconstitution and infusion convenience	Carbapenem positioning
Fetroja	Cefiderocol	Premix, compatibility, pharmacy efficiency	Narrower use and hospital adoption
Generic cefepime or piperacillin/tazobactam	Established beta-lactams	Low-cost ready-to-use products	Price and broad availability

Zerbaxa's clinical positioning is linked to resistant Gram-negative infections, including infections involving Pseudomonas aeruginosa. Commercially, formulation improvements would not replace antimicrobial stewardship or clinical differentiation. They would improve the product's operational value in hospitals where pharmacy time, dose accuracy, and preparation waste affect formulary decisions.

What is the revenue exposure to formulation competition?

Formulation competition would probably affect net price, hospital contracting, and utilization before it displaced the reference product entirely. The highest-risk segments are:

• Large hospital systems with centralized purchasing.
• Intensive-care units with frequent antibiotic preparation.
• Outpatient infusion providers.
• Hospitals using automated compounding.
• Markets where ready-to-administer competitors receive formulary preference.

A differentiated presentation could protect revenue by reducing total administration cost. A generic powder vial, by contrast, would compete primarily on acquisition price and could create rapid price erosion if multiple entrants launch.

Key Takeaways

• Zerbaxa's U.S. drug product contains ceftolozane sulfate and tazobactam sodium and lists no inactive ingredients.
• Its principal formulation weakness is the need for reconstitution and dilution before intravenous infusion.
• The most valuable commercial opportunities are ready-to-administer bags, dual-chamber systems, improved premixes, and faster-compounding vials.
• Aqueous stability, container compatibility, and in-use storage are the key technical barriers.
• Formulation patents would be strongest when tied to measurable improvements in stability, impurity control, reconstitution, or administration.
• Zerbaxa faces generic rather than biosimilar competition.
• FDA Orange Book listings, Paragraph IV filings, patent litigation, and settlement agreements must be reviewed together when assessing launch timing.
• Manufacturing complexity may limit the number of viable generic entrants.
• Licensing value is highest for technologies that improve both Zerbaxa preparation and the broader unstable-injectable antibiotic portfolio.

FAQs

Can Zerbaxa be reformulated as a premixed infusion?

Yes, but the key barrier is maintaining ceftolozane and tazobactam stability in an aqueous solution through storage, transport, and administration. A dual-chamber bag may offer a more practical route because it separates the dry product from the diluent until use.

Does Zerbaxa contain sodium from excipients?

The U.S. product contains tazobactam sodium, and the labeled diluents may contain sodium chloride. The prescribing information does not list separate inactive ingredients in the vial.[1]

Is Zerbaxa eligible for biosimilar competition?

No. Zerbaxa is a small-molecule antibacterial combination. Competitive applications would generally proceed through the generic drug pathway rather than the biosimilar pathway.

Could a generic Zerbaxa avoid formulation patents?

A generic applicant may design around formulation or presentation claims, provided the alternative product satisfies pharmaceutical-equivalence, quality, labeling, and regulatory requirements. Active-ingredient, combination, manufacturing, and method-of-use patents could still affect launch timing.

What hospital setting offers the best market for a Zerbaxa ready-to-use product?

Large hospitals, intensive-care units, centralized pharmacy operations, and outpatient infusion providers offer the clearest opportunity because they can capture savings from reduced compounding labor, lower preparation waste, and fewer administration steps.

References

1. U.S. Food and Drug Administration. (2024). Zerbaxa (ceftolozane and tazobactam) prescribing information. Merck & Co., Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/

2. U.S. Food and Drug Administration. (2014). FDA approves Zerbaxa to treat certain complicated infections. https://www.fda.gov/

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm